All news

Sputnik V shows 97.2% efficacy during vaccination in Belarus — RDIF

According to the Fund, the efficacy of Sputnik V was measured based on data from more than 860,000 people vaccinated between January and July 2021

MOSCOW, September 15. /TASS/. Russia’s Sputnik V vaccine demonstrated 97.2% efficacy against coronavirus and a high safety profile during vaccination in Belarus, according to the statement from the Russian Direct Investment Fund (RDIF).

"The Russian vaccine has demonstrated 97.2% efficacy against coronavirus in Belarus. The efficacy of Sputnik V was measured based on data from more than 860,000 people vaccinated between January and July 2021," the statement said.

Belarus was the first foreign country to register Sputnik V and use it for vaccination of the population, the Fund noted.

According to the report, "RDIF and partners have facilitated the technology transfer to localize the production of Sputnik V by Belarus’s Belmedpreparaty company, which is successfully manufacturing Sputnik V. In April 2021 the vaccine produced in Belarus was authorized by the Ministry of Health."

A single-component vaccine Sputnik Light (the first component of the Sputnik V vaccine) has also been registered in Belarus.